The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase receptor (TKI) therapy.
Description: Proportion (%) of patients with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI)
Measure: Proportion (%) of patients with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) Time: up to one yearDescription: Severity of (S)AEs
Measure: Severity of (S)AEs Time: up to one yearDescription: ORR (Objective response rate), if available
Measure: ORR (Objective response rate), if available Time: up to one yearDescription: PFS (Progression free survival), if available
Measure: PFS (Progression free survival), if available Time: up to one yearCase-Only
There is one SNP
Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or After EGFR Tyrosine Kinase Receptor (TKI) Therapy. --- T790M ---
KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy) The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase receptor (TKI) therapy. --- T790M ---
Inclusion Criteria: - 1. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy - 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: - 1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug - 2. Pregnancy and/or breast feeding - 3. Current participation in any interventional trial Inclusion Criteria: - 1. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy - 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: - 1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug - 2. Pregnancy and/or breast feeding - 3. Current participation in any interventional trial Non-Small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- T790M ---
Inclusion Criteria: - 1. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy - 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: - 1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug - 2. Pregnancy and/or breast feeding - 3. Current participation in any interventional trial Inclusion Criteria: - 1. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy - 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: - 1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug - 2. Pregnancy and/or breast feeding - 3. Current participation in any interventional trial Non-Small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- T790M --- --- T790M ---